Unicycive Therapeutics (NASDAQ:UNCY) Releases Quarterly Earnings Results, Misses Estimates By $0.36 EPS

Unicycive Therapeutics (NASDAQ:UNCY) issued its quarterly earnings data on Monday. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.36), FiscalAI reports.

Unicycive Therapeutics Stock Performance

NASDAQ:UNCY opened at $6.39 on Monday. The stock’s 50 day simple moving average is $6.66 and its 200-day simple moving average is $5.74. Unicycive Therapeutics has a 12-month low of $3.71 and a 12-month high of $11.00. The firm has a market cap of $137.32 million, a P/E ratio of -1.62 and a beta of 1.82.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of institutional investors have recently added to or reduced their stakes in UNCY. State Street Corp lifted its holdings in shares of Unicycive Therapeutics by 19.0% in the 4th quarter. State Street Corp now owns 65,227 shares of the company’s stock valued at $376,000 after buying an additional 10,400 shares during the period. Lazard Asset Management LLC acquired a new position in shares of Unicycive Therapeutics during the 2nd quarter worth $55,000. JPMorgan Chase & Co. increased its holdings in shares of Unicycive Therapeutics by 11,698.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after purchasing an additional 21,525 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in Unicycive Therapeutics during the fourth quarter worth about $226,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Unicycive Therapeutics in the third quarter valued at approximately $182,000. Hedge funds and other institutional investors own 40.42% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Guggenheim reaffirmed a “buy” rating on shares of Unicycive Therapeutics in a research note on Tuesday, December 30th. Westpark Capital began coverage on Unicycive Therapeutics in a research note on Thursday, February 19th. They issued a “buy” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Unicycive Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $34.33.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.